AstraZeneca's GLP-1 Pill Cuts Weight 11% and Lowers Blood Sugar in Phase 2 Trials

AstraZeneca's oral GLP-1 receptor agonist elecoglipron is generating attention after two Phase 2 trials demonstrated meaningful reductions in body weight and blood sugar, adding a potential new competitor to the rapidly expanding market for obesity and diabetes medications.

In the VISTA trial focused on obesity, patients taking the highest dose of elecoglipron lost an average of 11.2% of their body weight after 36 weeks. This figure includes all enrolled patients regardless of whether they stopped taking the drug — a conservative and rigorous way to report results. For context, Eli Lilly's approved oral GLP-1 pill Foundayo achieved the same 11.2% weight loss rate, though that was in a Phase 3 trial running 72 weeks, making direct comparison difficult.

The SOLSTICE trial, focused on type 2 diabetes, showed the highest dose of elecoglipron reduced A1C levels by up to 1.74 percentage points over 26 weeks. Importantly, the trial included an open-label comparator group taking oral semaglutide (oral Ozempic), which achieved a smaller 1.32-point A1C reduction — suggesting elecoglipron may have a glycemic advantage, though open-label comparator designs introduce bias.

Both studies were published simultaneously in The Lancet and presented at the American Diabetes Association's annual meeting, lending credibility to the findings. However, Phase 2 trials are designed to assess preliminary efficacy and dose-finding, not to serve as definitive proof of superiority over existing treatments.

For health-conscious individuals tracking the GLP-1 landscape, elecoglipron represents a potentially meaningful addition to oral options for managing weight and metabolic health. Broader Phase 3 data will be essential before any clinical conclusions can be drawn, and long-term safety data remains outstanding.